Wolff-Parkinson-White Syndrome

The global electrophysiology market is poised for significant growth, projected to expand from USD 4,350.7 billion in 2024 to USD 9,078.4 billion by 2034, at a robust CAGR of 7.6%. This remarkable growth is driven by the rising adoption of minimally invasive electrophysiology therapies for cardiac diagnostics and ablation procedures. Electrophysiology laboratory devices emerged as the dominant segment, accounting for the largest market share. Increasing demand for advanced diagnostic tools and efficient treatment options for cardiac arrhythmias is fueling innovation and adoption across the global healthcare landscape. NEWARK, DE / ACCESSWIRE / December 17, 2024 / The global Electrophysiology Market is expected to experience robust growth from 2024 to 2034, driven by advancements in medical technology, rising prevalence of cardiovascular diseases, and increased demand for minimally invasive procedures. The market size in 2024 is projected to be USD 4,350.7 billion and is expected to reach USD 9,078.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 7.6%. This growth is primarily fueled by innovations in electrophysiology devices, the aging population, and increasing awareness about the importance of heart health.Electrophysiology is a critical segment in the healthcare industry, encompassing technologies and treatments used to diagnose and treat heart rhythm disorders. The rising global burden of cardiovascular diseases is a major factor propelling market growth. Additionally, advances in diagnostic devices, such as electrophysiology catheters and 3D mapping systems, are significantly contributing to the market's expansion. The increasing number of healthcare facilities and the growing adoption of minimally invasive techniques are also boosting demand for electrophysiology services.The market is experiencing heightened activity from both established and emerging companies in the medical device sector, focusing on enhancing product offerings and expanding geographical reach. Innovations in electrophysiology devices, particularly those that offer enhanced precision and improved patient outcomes, are expected to dominate market trends over the coming years. The integration of artificial intelligence (AI) and machine learning (ML) in electrophysiology diagnostics is opening up new opportunities for growth and development in the industry.As healthcare systems worldwide continue to evolve, there is a growing need for more efficient, cost-effective treatment options, particularly for cardiovascular diseases. This demand for advanced diagnostic tools and treatments is expected to remain strong, driving the electrophysiology market's growth trajectory through 2034. The increasing importance of personalized medicine and the integration of telemedicine platforms into patient care will also play pivotal roles in shaping the market's future.What Is The Extent Of The Minimal Invasive Electrophysiology Procedure Impacting The Market?The invasive surgical interventions are associated with several risks for patients with pre-existing medical comorbidities such as hypertension, diabetes, etc. Also, the prevalence of cardiac arrhythmias including atrial fibrillation, atrial flutter, Wolff-Parkinson-White syndrome, and others is on its rise, therefore, it necessitates a safer, cost-effective and minimally invasive interventional procedure for the cardiac arrhythmia.The American Heart Association has stated that over 2.7 million Americans suffers from atrial fibrillation. The minimally invasive technology offered by cardiac ablation catheters and diagnostic catheters imperatively drive the electrophysiology market's growth spurt. The manufacturers are focused to provide advanced ablation and diagnostic catheters, and devices which are minimally invasive and offers a short recovery period. Key Takeaways from Market Study:Increased Adoption of Minimally Invasive Techniques: Growth in non-invasive diagnostic and therapeutic methods.Technological Innovations: AI, machine learning, and robotic assistance are reshaping electrophysiology procedures.Healthcare Accessibility: Expanding healthcare infrastructure in emerging markets is boosting the demand for electrophysiology treatments.Cardiovascular Disease Burden: Rising global cardiovascular diseases continue to drive demand for electrophysiology services."The Electrophysiology Market is set to experience significant growth over the next decade due to the increasing prevalence of cardiovascular diseases and the rapid advancements in medical technologies. Key players are investing heavily in product innovation, particularly in electrophysiology catheters and imaging systems, as these technologies offer higher precision, shorter recovery times, and improved patient outcomes. Moreover, the integration of AI and robotics is likely to revolutionize diagnostic and treatment capabilities in the near future, further driving market expansion." Says Sabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.)Get Complete Full Report: https://www.futuremarketinsights.com/reports/electrophysiology-marketWhat is the Commercial Potential of the Smart Technologies in Electrophysiology Devices?Manufacturers are increasingly including smart and next-generation technologies. The advanced cardiac electromapping machines equipped with next generation basket catheter scanning offers expedited, detailed and efficient cardiac tissue mapping. The advanced technology of contact force-sensing ablation catheters offers high precision lesion formation.Manufacturers have been seen at the forefront to strengthen their electrophysiology portfolio. Several companies have undergone acquisitions to expand their electrophysiology offerings. For instance, On June 05, 2018, Philips Healthcare acquired EPD, to strengthen the electrophysiology ablation image-guiding systems. Baylis Medical and Japan Lifeline collaborated to penetrate their advanced electrophysiology procedure solutions in the Europe and North America region.Several players such as Johnson & Johnson (Biosense Webster, Inc.), Abbott Laboratories, Acutus Medical Inc. and Microport Scientific Corporation have recently earned approvals and launched multiple electrophysiology catheters and mapping systems.How are Innovations Driving Electrophysiology Market?Manufacturers are focusing on alleviating issues associated with the conventional cardiac ablation catheters, diagnostic catheters, cardiac mapping machine, and access devices. The electrophysiology market has been introduced with next-generation electrophysiology devices, loaded with advanced features that offer elevated safety and precision.The conventional ablation catheters have been associated with off-targeting ablations, burns and limited flexibility to access the target tissue site. The latest ablation catheters include contact force-sensing technology which provides control and precision for ablation, balloon inflation pulmonary vein isolation that allows to access the challenging anatomy of the target tissue, and irrigated tip technology avoids ablation induced burns to the healthy cardiac tissues. Such advanced technology elevates the adoption of catheter ablation procedures by nullifying the potential risks.The cradiac electromapping machines are loaded with next-generation basket catheter which rapidly scans cardiac tissues point-by-point, also the use of a magnetic sensor or use of multiple ultrasound electrode basket for expedited and precise scanning.Medical devices in this decade are getting smarter, which are not just technological advancements, but also an essentiality amid the challenges of the pandemic. The interventionalists cannot afford to delay the cardiac therapies and on the same time, the hospital visits are also needed to be restricted to avoid hospital-acquired infection. Manufacturers have started including digital cloud technology to access and manage electrophysiology data for the monitoring of the cardiac rhythm data. This nullifies the need of physically visiting the interventionalist.Country-wise InsightsNorth America is well known for its strong healthcare infrastructure, emphasis on research and development, and availability of cutting-edge medical technologies. The electrophysiology market in the region is growing as a result of a favourable environment for the adoption of innovative treatment approaches such as electrophysiology. The expanding prevalence of arrhythmias, the increasing number of ablation facilities and procedures, and the increased use of electrophysiology equipment are all driving the market in Europe. Meanwhile, the Asia-Pacific electrophysiology business is expected to provide opportunities for prominent manufacturers looking to expand their reach. The increasing frequency of atrial fibrillation, a growing senior population, rising healthcare costs, and technological breakthroughs in electrophysiology are some of the main drivers driving market expansion.CountryCAGR (2024 to 2034)United States9.6%Germany9.9%France8.7%India7.9%Canada8.8%Component Insights:Electrophysiology Catheters: These devices are crucial for diagnosing and treating arrhythmias and are expected to dominate the market due to the increasing demand for minimally invasive procedures.Electrophysiology Mapping Systems: With the development of 3D mapping systems, healthcare professionals can now provide more accurate and efficient treatment, which is driving the demand for these systems in electrophysiology applications.Cardiac Ablation Devices: These devices, used to treat arrhythmias by destroying problematic tissue, are seeing a significant rise in adoption, particularly as the global demand for treatments for atrial fibrillation increases.Wearable Devices: Devices that monitor heart rhythm abnormalities and provide data for real-time analysis are expected to witness substantial growth due to the increasing adoption of preventive healthcare.What are the key drivers of atrial fibrillation prevalence in emerging economies?The prevalence of atrial fibrillation (AF) in emerging economies is influenced by several key drivers, which contribute to the increasing incidence and impact of this condition. Here are the primary factors:1. Aging PopulationAs populations in emerging economies age, the incidence of AF rises. Older adults are at a higher risk for developing AF due to age-related changes in cardiac structure and function.2. Increasing Rates of HypertensionHypertension is a significant risk factor for AF, accounting for a large percentage of cases globally. In many emerging economies, the prevalence of hypertension is rising due to lifestyle changes, urbanization, and increased stress levels, contributing to higher AF rates3. Obesity and Lifestyle ChangesThe growing prevalence of obesity in emerging economies is linked to sedentary lifestyles and dietary changes. Obesity is associated with several cardiovascular risk factors, including hypertension and diabetes, which can lead to AF4. Alcohol ConsumptionIncreased alcohol consumption has been observed in many emerging markets, which can exacerbate the risk of AF. Alcohol is known to trigger episodes of AF and contribute to overall cardiovascular health deterioration5. Healthcare Access and UnderdiagnosesLimited access to healthcare services in some regions can lead to underdiagnoses and under treatment of AF. Many patients with AF may remain undiagnosed due to inadequate screening practices or lack of awareness among healthcare providersNotable Developments in the Electrophysiology MarketIn May 2022, BioSig Technologies, Inc., a medical technology company, released a commercial launch campaign. The company has previously contributed to many impactful initiatives to expedite the sales of the PURE EP system. The device has been approved by Food and Drug Administration 510(k), and it focuses on driving procedural efficacy and efficiency in cardiac electrophysiology.In November 2021, India Medtronic Private Limited, which is a wholly-owned subsidiary of Medtronic plc, released the Arctic Front Cardiac Cry Ablation Catheter System. This is the first cry balloon catheter that has been approved by CDSCO to treat atrial fibrillation in India.Key Electrophysiology CompaniesAbbott LaboratoriesJohnson & Johnson (Biosense Webster, Inc.)Medtronic PlcBoston Scientific CorporationJapan LifelineKoninklijke Philips N.V.Merit Medical SystemsBiotronik SE & Co. KGMicroport Scientific CorporationAPN Health, LLCBaylis Medical Company, Inc.OthersOld Source: Electrophysiology Market is poised to reach US$ 22.67 billion by 2033Key Segments in the Electrophysiology Market ReportBy Product Type:Electrophysiology Laboratory Devices3D Mapping SystemsElectrophysiology Recording SystemsRadiofrequency (RF) Ablation SystemsIntracardiac Echocardiography (Ice) Ultrasound Imaging SystemsCardiac StimulatorsOthersElectrophysiology Ablation CathetersCryoablation Electrophysiology CathetersRadiofrequency (RF) Ablation CathetersIrrigated Tip RF Ablation CathetersLaser Ablation CathetersElectrophysiology Diagnostic CathetersConventional Electrophysiology Diagnostic CathetersAdvanced Electrophysiology Diagnostic CathetersUltrasound Electrophysiology Diagnostic CathetersAccess DevicesBy Indication:Atrial FibrillationAtrial FlutterWolff-Parkinson-White Syndrome (WPW)Atrioventricular Nodal Reentry Tachycardia (AVNRT)Ventricular tachycardia (VT)OthersBy End User:HospitalsCardiac Catheterization LaboratoriesAmbulatory Surgery CentersBy Region:North AmericaLatin AmericaEuropeAsia PacificMiddle East and AfricaAuthorSabyasachi Ghosh (Associate Vice President at Future Market Insights, Inc.) holds over 12 years of experience in the Healthcare, Medical Devices, and Pharmaceutical industries. His curious and analytical nature helped him shape his career as a researcher.Identifying key challenges faced by clients and devising robust, hypothesis-based solutions to empower them with strategic decision-making capabilities come naturally to him. His primary expertise lies in areas such as Market Entry and Expansion Strategy, Feasibility Studies, Competitive Intelligence, and Strategic Transformation.Holding a degree in Microbiology, Sabyasachi has authored numerous publications and has been cited in journals, including The Journal of mHealth, ITN Online, and Spinal Surgery News.Explore FMI's Extensive Coverage in the Healthcare Domain:The visual electrophysiology market is anticipated to flourish at a steady CAGR of 7.0% between 2023 and 2033.The global Hospital Workforce Management Market is expected to be valued at USD 1,533.2 million in 2023.The non-hospital-based point-of-care diagnostic products market is likely rise to a USD 12.9 billion valuation in 2022.The global demand for hospital supplies is expected to increase at 3.7% CAGR over the forecast period from 2022 to 2032.Future Market Insights' updated report on the electronic medical record ecosystem highlights various opportunities and growth spots for the coming decade.The global medical automation market is estimated to secure a valuation of USD 48,626.2 million in 2023 and reach up to USD 103,052.3 million by 2033.The global Portable Medical Devices Market is projected to expand at a CAGR of 10.7% during the forecast period.The global Cardiac Assist Devices Market is poised to surpass USD 1.37 billion by 2023, surging at a remarkable CAGR of 6.1% through 2033 to reach USD 2.48 billion.In a recently updated edition, trends infer a valuation of USD 1,175.10 million for the mobile cardiac telemetry system market in 2024. Looking ahead to 2034The global cardiac surgery devices market is expected to enjoy a valuation of USD 1.7 Billion by the end of 2022About Future Market Insights (FMI)Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai and has delivery centres in the United Kingdom, the United States, and India. FMI's latest market research reports and industry analysis helps businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.Join us as we commemorate 10 years of delivering trusted market insights. Reflecting on a decade of achievements, we continue to lead with integrity, innovation, and expertise.Contact UsFuture Market Insights Inc.Christiana Corporate, 200 Continental Drive,Suite 401, Newark, Delaware - 19713, USAT: +1-347-918-3531For Sales Enquiries: [email protected]Website:https://www.futuremarketinsights.comLinkedIn| Twitter| Blogs | YouTubeSOURCE: Future Market Insights, Inc.

Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 SAN DIEGO, CA, USA I November 12, 2024 I Avidity Biosciences, Inc. (Nasdaq: RNA ), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart. Avidity is advancing its first two new wholly-owned precision cardiology development candidates targeting rare genetic cardiomyopathies: AOC 1086 targeting PLN (phospholamban) cardiomyopathy and AOC 1072 targeting PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome. In addition, Avidity shared preclinical data from next-generation technology innovations demonstrating improved siRNA delivery and increased durability. “Today marks a key milestone for Avidity as we leverage the broad utility of our proprietary AOC platform to address the underlying cause of genetic heart diseases in precision cardiology,” said Sarah Boyce, president and chief executive officer at Avidity Biosciences. “We are proud to be the first company to successfully deliver siRNA directly to skeletal muscle and now, we have demonstrated that we can deliver siRNA against targets in the heart in preclinical studies. With continued innovations to our AOC technology, we are expanding on the possibilities of RNA delivery. These advancements further our mission to profoundly improve people’s lives by revolutionizing a new class of targeted RNA therapeutics.” AOC 1072 and AOC 1086 are designed to deliver siRNA directly to the heart muscle to knock down specific disease-causing genetic mutations that cause rare genetic cardiomyopathies. In preclinical studies, AOC 1086 and AOC 1072 demonstrated robust siRNA delivery to the heart muscle and potent targeted knockdown of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA. AOC 1086 and AOC 1072 were well tolerated without any effect on electrocardiogram parameters for evaluating cardiac safety in preclinical studies. Preclinical data from AOC 1072 targeting PRKAG2 will be presented at the American Heart Association (AHA) Scientific Sessions 2024 on November 16 in Chicago, Illinois. Avidity also shared a first-look at next-generation technology innovations, including siRNA modifications and evolved antibody engineering, which, in preclinical studies provided up to 30-fold increase in siRNA delivery in skeletal muscle, and greater durability with sustained target inhibition for three months. Advancements in siRNA delivery and greater durability allow the opportunity for less frequent dosing and improved patient convenience. Video Webcast Information The company is hosting Volume 11 of its investor and analyst event series on November 12, 2024, beginning at 8:00 a.m. ET to discuss preclinical data on AOC 1072 and AOC 1086, along with platform innovations. The virtual event will be available via a live video webcast and can be accessed here or from the “ Events and Presentations ” page in the “Investors” section of Avidity’s website. A replay of the webcast will be archived on Avidity’s website following the event. About PLN Cardiomyopathy PLN (Phospholamban) Cardiomyopathy is an autosomal dominant, progressive cardiac disease caused by a mutation on the PLN gene. The most common disease variant is the R14del, causing a buildup of toxic protein aggregates that trigger cardiomyocyte death leading to dilation of the heart chambers, arrhythmias (irregular heartbeats), sudden cardiac arrest and heart failure. There are no FDA-approved disease-modifying therapies for PLN cardiomyopathy, and current standard of care focuses on symptom management with medications or invasive treatments including pacemakers or implantable cardioverter defibrillator (ICD). Patients who develop progressive heart failure may require a heart transplant. About PRKAG2 Syndrome PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome is an autosomal dominant, progressive cardiac disease caused by a mutation on the PRKAG2 gene that results in increased AMP-activated protein kinase (AMPK) activity. This causes excessive cardiac glycogen storage in the heart, leading to cardiac hypertrophy (thickening of heart muscle) and multiple different types of arrhythmias (irregular heartbeats), including Wolff-Parkinson-White syndrome, atrial fibrillation, and cardiac conduction system disease. As a result, patients with PRKAG2 syndrome are at an increased risk of experiencing sudden cardiac arrest or heart failure. There are no FDA-approved disease-modifying therapies for PRKAG2 Syndrome, and current standard of care focuses on symptom management with medications or invasive treatments including pacemakers or implantable cardioverter defibrillator (ICD). Patients who develop progressive heart failure may require a heart transplant. About Avidity Avidity Biosciences, Inc.’s mission is to profoundly improve people’s lives by delivering a new class of RNA therapeutics – Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit www.aviditybiosciences.com and engage with us on LinkedIn and X . SOURCE: Avidity Biosciences

Avidity expands its leading RNA delivery technology into precision cardiology with two new wholly-owned development candidates targeting rare genetic cardiomyopathies: AOC 1086 to treat PLN Cardiomyopathy and AOC 1072 to treat PRKAG2 Syndrome AOC 1072 and AOC 1086 preclinical data demonstrated robust siRNA delivery to the heart and targeted knockdown with potent reduction of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA Avidity introduces next-generation technology innovations demonstrating improved siRNA delivery in skeletal muscle and increased durability in preclinical studies AOC 1072 preclinical data will be presented at American Heart Association (AHA) Scientific Sessions 2024 Volume 11 of virtual investor and analyst series today, Tuesday, Nov. 12 at 8:00 a.m. ET SAN DIEGO, Nov. 12, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide Conjugates (AOCs™), today announced it has expanded beyond rare skeletal muscle disorders and is opening up a new therapeutic field, precision cardiology, to address the root cause of genetic diseases of the heart. Avidity is advancing its first two new wholly-owned precision cardiology development candidates targeting rare genetic cardiomyopathies: AOC 1086 targeting PLN (phospholamban) cardiomyopathy and AOC 1072 targeting PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome. In addition, Avidity shared preclinical data from next-generation technology innovations demonstrating improved siRNA delivery and increased durability. "Today marks a key milestone for Avidity as we leverage the broad utility of our proprietary AOC platform to address the underlying cause of genetic heart diseases in precision cardiology," said Sarah Boyce, president and chief executive officer at Avidity Biosciences. "We are proud to be the first company to successfully deliver siRNA directly to skeletal muscle and now, we have demonstrated that we can deliver siRNA against targets in the heart in preclinical studies. With continued innovations to our AOC technology, we are expanding on the possibilities of RNA delivery. These advancements further our mission to profoundly improve people's lives by revolutionizing a new class of targeted RNA therapeutics." AOC 1072 and AOC 1086 are designed to deliver siRNA directly to the heart muscle to knock down specific disease-causing genetic mutations that cause rare genetic cardiomyopathies. In preclinical studies, AOC 1086 and AOC 1072 demonstrated robust siRNA delivery to the heart muscle and potent targeted knockdown of approximately 80% in cardiac PLN mRNA and PRKAG2 mRNA. AOC 1086 and AOC 1072 were well tolerated without any effect on electrocardiogram parameters for evaluating cardiac safety in preclinical studies. Preclinical data from AOC 1072 targeting PRKAG2 will be presented at the American Heart Association (AHA) Scientific Sessions 2024 on November 16 in Chicago, Illinois. Avidity also shared a first-look at next-generation technology innovations, including siRNA modifications and evolved antibody engineering, which, in preclinical studies provided up to 30-fold increase in siRNA delivery in skeletal muscle, and greater durability with sustained target inhibition for three months. Advancements in siRNA delivery and greater durability allow the opportunity for less frequent dosing and improved patient convenience. Video Webcast Information The company is hosting Volume 11 of its investor and analyst event series on November 12, 2024, beginning at 8:00 a.m. ET to discuss preclinical data on AOC 1072 and AOC 1086, along with platform innovations. The virtual event will be available via a live video webcast and can be accessed here or from the "Events and Presentations" page in the "Investors" section of Avidity's website. A replay of the webcast will be archived on Avidity's website following the event. About PLN Cardiomyopathy PLN (Phospholamban) Cardiomyopathy is an autosomal dominant, progressive cardiac disease caused by a mutation on the PLN gene. The most common disease variant is the R14del, causing a buildup of toxic protein aggregates that trigger cardiomyocyte death leading to dilation of the heart chambers, arrhythmias (irregular heartbeats), sudden cardiac arrest and heart failure. There are no FDA-approved disease-modifying therapies for PLN cardiomyopathy, and current standard of care focuses on symptom management with medications or invasive treatments including pacemakers or implantable cardioverter defibrillator (ICD). Patients who develop progressive heart failure may require a heart transplant. About PRKAG2 Syndrome PRKAG2 (Protein Kinase AMP-activated non-catalytic subunit Gamma 2) Syndrome is an autosomal dominant, progressive cardiac disease caused by a mutation on the PRKAG2 gene that results in increased AMP-activated protein kinase (AMPK) activity. This causes excessive cardiac glycogen storage in the heart, leading to cardiac hypertrophy (thickening of heart muscle) and multiple different types of arrhythmias (irregular heartbeats), including Wolff-Parkinson-White syndrome, atrial fibrillation, and cardiac conduction system disease. As a result, patients with PRKAG2 syndrome are at an increased risk of experiencing sudden cardiac arrest or heart failure. There are no FDA-approved disease-modifying therapies for PRKAG2 Syndrome, and current standard of care focuses on symptom management with medications or invasive treatments including pacemakers or implantable cardioverter defibrillator (ICD). Patients who develop progressive heart failure may require a heart transplant. About Avidity Avidity Biosciences, Inc.'s mission is to profoundly improve people's lives by delivering a new class of RNA therapeutics - Antibody Oligonucleotide Conjugates (AOCs™). Avidity is revolutionizing the field of RNA with its proprietary AOCs, which are designed to combine the specificity of monoclonal antibodies with the precision of oligonucleotide therapies to address targets and diseases previously unreachable with existing RNA therapies. Utilizing its proprietary AOC platform, Avidity demonstrated the first-ever successful targeted delivery of RNA into muscle and is leading the field with clinical development programs for three rare neuromuscular diseases: myotonic dystrophy type 1 (DM1), Duchenne muscular dystrophy (DMD) and facioscapulohumeral muscular dystrophy (FSHD). Avidity is also advancing two wholly-owned precision cardiology development candidates addressing rare genetic cardiomyopathies. Avidity is broadening the reach of AOCs with its advancing and expanding pipeline including programs in cardiology and immunology through internal discovery efforts and key partnerships. Avidity is headquartered in San Diego, CA. For more information about our AOC platform, clinical development pipeline and people, please visit and engage with us on LinkedIn and X. Forward-Looking Statements Avidity cautions readers that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on the company's current beliefs and expectations. Such forward-looking statements include, but are not limited to, statements regarding: the ability of our AOC technology to develop precision cardiology therapeutics; the ability of AOC 1072 to target PRKAG2 Syndrome and the ability of AOC 1086 to target PLN cardiomyopathy; our ability to deliver siRNA to the heart; safety and tolerability results of our precision cardiology product candidates; the design and capabilities of AOC 1072 and AOC 1086; the effectiveness of AOC 1072 and AOC 1086; our next generation technology and its potential impact; the improved delivery and durability associated with our next generation technology; the design and capabilities of our next generation technology; and plans and objectives of management for future operations. The inclusion of forward-looking statements should not be regarded as a representation by Avidity that any of these plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Avidity's business and beyond its control, including, without limitation: the results of preclinical studies are not necessarily indicative of final results; further analysis of existing preclinical data and analysis of new data may lead to conclusions different from those established as of the date hereof, and such data may not meet Avidity's expectations; preclinical data related to Avidity's precision cardiology programs and next generation technology may not support the filing or approval of any IND; unexpected adverse side effects to, or inadequate efficacy of, Avidity's product candidates that may delay or limit their development, regulatory approval and/or commercialization; Avidity's approach to the discovery and development of product candidates based on its AOC™ platform is unproven; potential delays in the commencement, enrollment, data readouts and completion of preclinical studies or clinical trials; Avidity's dependence on third parties in connection with preclinical and clinical testing and product manufacturing; legislative, judicial and regulatory developments in the United States and foreign countries; Avidity could exhaust its available capital resources sooner than it currently expects; and other risks described in Avidity's Annual Report on Form 10-K for the fiscal year ended December 31, 2023 and subsequent filings with the SEC. Avidity cautions readers not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and the company undertakes no obligation to update such statements to reflect events that occur or circumstances that arise after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, which is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Investor Contact: Mike MacLean (619) 837-5014 [email protected] Media Contact: Navjot Rai (619) 837-5016 [email protected] SOURCE Avidity Biosciences, Inc. WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED